You've probably seen the sales pitch: NMN is the "next-generation" NAD+ booster, NR is the original, and nicotinamide is the budget option nobody cares about. A new randomized human trial from Nestlé researchers just scrambled that hierarchy. NR and NMN performed comparably at raising blood NAD+. Nicotinamide did not. And the likely reason involves your gut bacteria turning both supplements into something much cheaper and more familiar: nicotinic acid, a form of niacin.
The study was published in Nature Metabolism (2026;8(1):62-73) and is the first to compare all three precursors directly in people.
Why NAD+ Is Such a Big Deal
NAD+ (and its phosphorylated cousin NADP) are vitamin B3-derived cofactors involved in countless metabolic reactions and protein modifications. Disturbances in NAD+ balance have been linked to a range of health conditions, which is why the supplement industry has built an entire category around "restoring" it.
Three precursors dominate the market:
- Nicotinamide (Nam): the cheap, long-known form of vitamin B3
- Nicotinamide riboside (NR): the first widely marketed "NAD+ booster"
- Nicotinamide mononucleotide (NMN): the premium-priced challenger
Until now, the evidence for choosing among them came mostly from animal and cell studies. Human head-to-head data was missing.
The Study Design
Researchers ran a randomized, open-label, placebo-controlled trial in 65 healthy adults. Participants took Nam, NR, NMN, or placebo for 14 days. The team then went further than most supplement trials, adding two mechanistic layers:
- Ex vivo gut fermentation using human microbiota, to see what bacteria do to each compound.
- Whole-blood experiments, to test which compounds boost NAD+ directly in blood cells.
The trial is registered as NCT05517122. The abstract does not list exact doses, so check the full text for those.
The Results: A Tie, and a Loser
NR and NMN comparably increased circulating NAD+ after 14 days. Nicotinamide did not produce that sustained rise.
Nam wasn't inert, though. It was the only compound to acutely and transiently alter the whole-blood NAD+ metabolome, a short-lived spike in activity rather than a lasting elevation. The authors attribute this to Nam being rapidly absorbed and entering the salvage pathway quickly.
So the headline for shoppers: in this trial, there was no evidence that NMN outperforms NR on blood NAD+, despite the price gap commonly seen on shelves.
The Gut-Microbe Twist
Here's where it gets interesting. Recent rodent research had suggested that NR and NMN may work partly by being converted by gut microbes into nicotinic acid (NA). This study tested that idea in human material.
- In ex vivo fermentation with human microbiota, NR and NMN gave rise to NA and specifically enhanced microbial growth and metabolism.
- In whole blood ex vivo, NA was a potent NAD+ booster, while NMN, NR and Nam were not.
The authors propose a gut-dependent model: NR and NMN raise systemic NAD+ largely through the Preiss-Handler pathway (the route that starts with nicotinic acid), while quickly absorbed Nam acts acutely via the salvage pathway. The researchers describe a dual effect for NR and NMN: a sustained rise in systemic NAD+ plus a modulating effect on gut health via NA.
Note the careful wording: this is a proposed model built from a human trial plus ex vivo experiments. It is not proof that microbial conversion is the only route in a living person.
What It Means for the NMN vs NR Debate
If both compounds are funneled through similar microbial chemistry, the marketing arguments about NMN's "superior" absorption or NR's "better evidence" lose some force, at least for blood NAD+. On this evidence the two look interchangeable, so price and product quality become the main differentiators.
What It Means for Cheap Niacin
The uncomfortable implication for premium brands: if nicotinic acid is the potent NAD+ booster in blood, ordinary niacin may deserve a closer look. The study did not test niacin supplementation in humans, so it cannot say that niacin matches NR or NMN. But the mechanism raises a legitimate question that future trials should answer directly.
Limitations You Should Know
- Short duration: only 14 days. Long-term effects are unknown.
- Open-label: participants and researchers knew who received what, which can introduce bias, though blood NAD+ is an objective measure.
- Healthy adults only: results may not carry over to older people or those with metabolic disease.
- Surrogate endpoint: raising blood NAD+ is not the same as improving health outcomes.
- Industry funding: the authors are employees of Nestlé Research and Nestlé Health Science (plus one from Cryptobiotix). That doesn't invalidate the work, which was peer reviewed, but independent replication matters.
- Mixed evidence: ex vivo gut and blood experiments don't fully reproduce what happens in the body.
Practical Takeaways
This is general information, not medical advice. Talk to a clinician before supplementing, especially if you take medications or have a health condition.
- Pick the cheaper of NR or NMN. Based on this trial, neither showed a blood NAD+ advantage over the other. Choose a reputable brand with third-party testing.
- Don't count on plain nicotinamide for sustained NAD+ elevation. In this study it produced only a transient effect.
- Doses vary. Other human trials of NR and NMN have commonly used roughly 250 to 1,000 mg per day. That is general context from the wider literature, not the doses from this study, and not a recommendation.
- Gut health likely matters. If microbes do the conversion, your microbiome may influence how well these supplements work. That could partly explain why individual responses vary.
- Mind the niacin flush. Nicotinic acid is the form known for causing flushing (warmth, redness, itching). If you consider niacin as a cheaper route, speak to a doctor first, since high doses carry real risks and the flush is only one of them.
The Bottom Line
The first human head-to-head suggests the NMN vs NR rivalry is more of a draw than the marketing implies, and that your gut bacteria may be the hidden middlemen. It's a short, industry-funded study in healthy people, so treat it as a strong hypothesis-builder rather than the final word. The next big question: does plain niacin do the same job for less?
